Obesity is one of the major pandemics of the 21st century. Due to its multifactorial etiology, its treatment requires several actions, including dietary intervention and physical exercise. Excessive fat accumulation leads to several health problems involving alteration in the gut-microbiota-brain axis. This axis is characterized by multiple biological systems generating a network that allows bidirectional communication between intestinal bacteria and brain. This mutual communication maintains the homeostasis of the gastrointestinal, central nervous and microbial systems of animals. Moreover, this axis involves inflammatory, neural, and endocrine mechanisms, contributes to obesity pathogenesis. The axis also acts in appetite and satiety control and synthesizing hormones that participate in gastrointestinal functions. Exercise is a nonpharmacologic agent commonly used to prevent and treat obesity and other chronic degenerative diseases. Besides increasing energy expenditure, exercise induces the synthesis and liberation of several muscle-derived myokines and neuroendocrine peptides such as neuropeptide Y, peptide YY, ghrelin, and leptin, which act directly on the gut-microbiota-brain axis. Thus, exercise may serve as a rebalancing agent of the gut-microbiota-brain axis under the stimulus of chronic low-grade inflammation induced by obesity. So far, there is little evidence of modification of the gut-brain axis as a whole, and this narrative review aims to address the molecular pathways through which exercise may act in the context of disorders of the gut-brain axis due to obesity.

**KEYWORDS**

microbiota-gut-brain axis, exercise, obesity, gut-derived peptides, dysbiosis
Introduction

The obesity epidemic has reached over 2 billion people worldwide, with 39% of the world population being overweight. This number is expected to increase to 50% by 2030 (1). Obesity has multifactorial pathogenesis and is associated with pathologies characterized by metabolic disorders, such as type II diabetes (2, 3). In addition, obesity is associated with increased risk of stress, depression, anxiety, decreased satiety, and reduction of life expectancy (1). On the other hand, dietary control and increased energy expenditure through physical activity have been used as the main weight-reduction strategies (4, 5).

Obesity has been commonly associated with dysregulation of intestinal function, altered gut microbiota, and appetite dysregulation (6, 7). These physiologic responses are closely related, involving the gut microbiota, the gastrointestinal tract, and the brain, which compose the microbiota-gut-brain axis (MGB axis) (8). For example, a report on lean animals that for two weeks received a transplant of the fecal microbiota from obese animals led to a significant increase in body weight (9). More recently, studies have indicated that physical activity could attenuate the physiologic outcomes of obesity, which may be associated with a modulation of the MGB-axis (10–12). According to the literature, sedentary hypertensive animals (SHR) that received a transplant of fecal microbiota from SHR animals that performed physical exercise had attenuated systolic blood pressure and a change in the gut-brain axis through the modulation of the gut microbiota (13). It is believed that different exercise training variables (e.g., intensity, volume, type of exercise) may influence neurotransmitter signaling involved in appetite control, intestinal integrity, permeability, and alteration of the gut microbiota (14–16).

Although these responses have never been investigated collectively in a single study, it is believed that the modulation of the MGB-axis by physical activity can result in antagonistic reactions compared to changes due to obesity (7, 10, 17–19). Moderate exercise has been associated with improved gut health, intestinal permeability control, increased microbial variation, and appetite regulation (17, 20, 21). On the other hand, obesity is often associated with antagonistic characteristics such as increased intestinal permeability (leaky gut), dysbiosis, and appetite dysregulation (7, 22, 23). In this context, the present review will address the molecular mechanisms involved in modulating the MGB-axis by physical exercise and obesity and their contrasting points.

Microbiota-gut-brain axis

The foremost communicators between the brain and the gut (MGB-axis) are the central nervous system (CNS), the enteric nervous system (ENS), the autonomic nervous system (ANS), and the hypothalamic-pituitary-adrenal (HPA) axis (24), see Figure 1. The common feature of the MGB axis is the inclusion of gut microbes, metabolites, and gut peptides in gut-brain...
The impact of obesity on the microbiota-gut-brain axis

Deregulation of the MGB axis is associated with several metabolic and neurologic pathologies, such as Alzheimer's, Parkinson's, and obesity (37–39). After food consumption, sensory information crosses the NV and is sent to the nucleus tractus solitarius (NTS). NTS neurons integrate the incoming vagal information with another neuroendocrine signal into the hypothalamus (40). Energy balance signaling in the hypothalamus (via NTS neurons) can recognize changes in dietary pattern (41). For example, increased chronic intake of hypercaloric diets can modulate the communication of the NS pathway, which can cause a hormonal imbalance related to appetite control, leading the individual to obesity (41, 42).

The hypothalamus is considered the “command center” of satiety and energy expenditure (42). Changes in the hypothalamus signaling will reflect on the received stimulus (43). In this regard, obesity can dysregulate several peptides or their receptors that are known to decrease food intake, such as nesfatin-1, oxymyotominulin (OXM), CCK, glucagon-like peptide 1 (GLP-1), pancreatic polypeptide (PP), and PYY (44), as shown in Table 1. By changing these molecules, obesity leads to deficient signaling to the hypothalamus, causing hypothalamic dysfunction and energy imbalance (62, 63).

The high caloric consumption in the Western diet can cause an inflammatory environment in the digestive tract associated with microbiome disturbances (64). In this sense, saturated long-chain fats can activate toll-like receptors 4 (TLR4) and initiate an inflammatory process in astrocytes, microglia, and neurons (65). Inflammation of the hypothalamus is characterized by exacerbated proliferation of glial cells, infiltration of microglia, and proliferation of astrocytes (65, 66). Hypothalamic inflammation caused by obesity generates mitochondrial dysfunction (62). The melanocortin system consists of several critical neuronal populations that participate in hypothalamic mitochondrial regulation (67) and are located in the agouti-related protein (AgRP)/neuropeptide Y (NPY) and proopiomelanocortin (POMC)/cocaine- and amphetamine-regulated transcript (CART) neurons (Figure 2). In response to food consumption, the α-melanocyte-stimulating hormone (α-MSH) is released from POMC/CART-expressing neurons. It binds to melanocortin receptors 3 and 4 (MC3/4R), reducing appetite and increasing energy expenditure (68). The opposite occurs with AgRP/NPY-expressing neurons, which release AgRP neuropeptides that bind to MC4R and inhibit POMC neurons, stimulating hunger and decreasing energy expenditure (68). Thus, several studies have sought to understand MC4R signaling pathways due to their importance in regulating appetite and obesity (69–71).

Nesfatin-1 is an anorectic neuropeptide associated with appetite regulation, malnutrition, and weight reduction (see Figure 2). The reduction of nesfatin-1 has been identified in overweight and obese children, adolescents, and adults (72, 73). Nesfatin-1 is derived from nucleobindin-2 (Nucb2) mRNA. Nucb2 reduction is also identified in obese people; interestingly, this reduction can lead to insulin resistance (74). Recently, it was identified that Nucb2/Nesfatin-1 is reduced in the hypothalamus of obese individuals (75). Also, an increase in nesfatin-1 in the brain leads to activation of the insulin receptor (InsR)/insulin receptor substrate-1 (IRS-1), increasing insulin sensitivity (76). Thus, this peptide appears to be a target for regulating appetite and glycemic control (77, 78).

Several peptides can be altered due to obesity (79). Enteroendocrine cells (EEC) release the hormone GLP-1, which acts on gastric reduction, satiety control, and decreased apoptosis of pancreatic beta cells (80). GLP-1 is reduced in obese people (81). It was recently identified that applying subcutaneous injections of GLP-1 receptor agonist exenatide 2 mg (ExQW) once a week and over 36 weeks leads to a reduction in the total adipose tissue waist circumference of obese
TABLE 1 Functions of hormones/peptides and possible changes due to obesity.

| Hormone / peptide | Secreting body | Function | Contributing factor | Influence of obesity | Author |
|-------------------|----------------|----------|---------------------|----------------------|--------|
| Ghrelin           | Stomach        | Meal starter; long-term regulation of body weight, energy fuel division. | Hypercaloric / hyperlipidic diet | ↑ Levels and acceleration of gastric emptying | (45) |
| Peptide YY (PYY)  | Intestine      | Meal inhibitor; ↑ satiety; ↑ intestinal motility | Snack hypercaloric 2000 kcal | ↑ Plasma PYY after meal and fasting | (46) |
| Glucagon like peptide-1 (GLP-1) | Large intestine | ↑ In the release of insulin; inhibition of gastric emptying and secretion of gastric acid in the stomach; ↑ satiety in the brain; | Liraglutide | Suppression in the concentrations of GLP-1 | (47) |
| Cholecystokinin (CCK) | Small intestine | Stimulates the contraction of the gallbladder; ↑ satiety; ↑ the secretion of pancreatic enzymes for digestion of carbohydrates, proteins and fats; | – | ↓ CCK release, stimulating ghrelin secretion. | (48) |
| Pancreatic polypeptide (PP) | Pancreas | ↑ Energy expenditure; ↑ satiety; suppression of pancreatic secretion; stimulation of gastric secretion; | Hypercaloric / hyperlipidic diet | ↑ PP | (49) |
| Oxytomodulin (OXM) | Small intestine | ↑ Energy expenditure; ↑ satiety; suppression of pancreatic secretion; stimulation of gastric secretion; | Infusion of PYY and OXM | ↓ OXM. Infusions result in ↓ energy intake. | (50) |
| Gastrointestinal polypeptide or glucose-dependent insulinotropic (gip) | Large intestine | Inhibits water absorption; ↑ stimulating lipase. | High-fat diet | ↑ GIP concentration: ↓ visceral and hepatic fat, ↑ blood flow in adipose tissue; | (51) |
| Gastrin           | Small intestine | ↑ Intestinal motility; stimulates the growth of the intestinal mucosa; | High-fat diet | ↓ Gastrin, weight gain. | (52) |
| Leptin            | Stomach        | Control of energy intake; ↑ satiety; | High-fat diet | ↓ Circulating levels, resistance to its capture. | (53) |
| Adiponectin       | Blood flow     | Glycemia regulation; fatty acid catabolism; ↑ insulin sensitization; | Thiazolidinediones or CBl antagonists (rimonabant) increase a plastic adiponectin | ↓ Adiponectinemia, contributing to the pathogenesis of insulin resistance, type 2 diabetes, cardiovascular disease in obese or overweight people | (54) |
| Insulina          | Adipose tissue/ pancreas | ↓ Blood glucose control; lipid storage | High-fat diet | Insulin resistance, ↓ the body's glucose uptake | (55) |
| Neuro peptide Y (NPY) | Adipose tissue | ↑ In energy storage; ↑ in food intake; | Hypercaloric / hyperlipidic diet | ↓ Levels, triggering weight gain | (56) |
| Melanocortin      | Adipose tissue | Energy balance regulation | – | ↑ Melanocortin and the MC4R gene | (57) |
| Ileit amyloid polypeptide (IAPP) or amylin | Stomach | Gastric acid secretion; inhibition of gastric emptying; release of glucagon; ↓ of food intake; ↓ weight gain and adiposity | – | Plasma levels are ↑ in obese individuals | (58) |
| Orexin or hypocretin | Stomach/ intestine | Regulation of intestinal motility; regulation in pancreatic secretion; regulation of food intake; | Hyperlipidemic diet | ↓ In plasma levels, which can ↓ energy expenditure. | (59) |
| Visfatin (VF)     | Adipose tissue | Glucose regulation; insulin-like action; | Hyperlipidemic diet | ↓ Plasma concentrations, triggering ↓ glucose sensitivity | (60) |
| Nesfatin-1        | Hypothalamus   | Appetite regulator; energy homeostasis regulator; | Hyperlipidemic diet | In obese people the concentration is ↑, ↓ food intake ↓ satiety; | (61) |

↑ - increase and greater; ↓ - decrease and decline; (↑) Increase Secretion and Greater; (↓) Decrease Secretion and Decline.

individuals (82). In this context, the pharmacological manipulation of GLP-1 receptor agonists as a target in taste perception and weight loss has recently emerged (47, 83). PYY and cholecystokinin (CCK) peptides are also related to appetite control and decreased gastric secretion (84, 85). In obese individuals, PYY and CCK are usually reduced (45, 46). Animals with the inhibited CCK receptor (knockout model) tend to acquire obesity and develop non-insulin-dependent diabetes mellitus (86). Interestingly, these animals also contain an elevation of neuropeptide Y (NPY) mRNA expression in the dorsomedial hypothalamic (DMH) area (86). This peptide increases appetite and is commonly overexpressed in obese people (87). PYY and NPY are similar peptides sharing the same receptors (Y1-Y3 and Y5 receptors) (88), as shown in Figure 2. Obesity increases peripheral NPY in adipose tissue macrophages with autocrine and paracrine signals (89). Besides,
adipose Y5R mRNA is higher in obese than non-obese individuals (90). Thus, a drug induction strategy with antagonistic effects of neuropeptide receptors has emerged as an anti-obesity treatment (91, 92).

Ghrelin and leptin are other peptides that significantly impact satiety control (Table 1). These two hormones are related to food intake and body weight (93). Ghrelin is an orexigenic hormone that acts on the hypothalamus’s arcuate nucleus (Arc) in response to fasting. Ghrelin stimulates the GH secretion of growth hormone (GH) by the GH secretagogue-receptor (GHS-R). Obese people have low ghrelin levels and leptin resistance (lower leptin receptor expression, Lep-R) (94, 95). A higher circulating leptin level is considered a marker of uncontrolled eating in these individuals.

Furthermore, as a result of ghrelin reduction, obese people also have a GH deficiency (96). Recently, it has been identified that the synthetic GHSR agonist (hexarelin) reduces fat accumulation and improves insulin sensitivity in obese mice (97). Although drug treatments for obesity have shown promise, they are not yet effective in slowing the disease progression and require multiple health domains extending beyond weight reduction (98). Fat accumulation leads to intestinal, hypothalamic, and systemic inflammation (99, 100). Excessive triglyceride in fat cells increases the release of tumor necrosis factor-alpha (TNF-α) and pro-inflammatory interleukins and decreases the expression of anti-inflammatory molecules such as adiponectin (101). These pro-inflammatory adipokines participate in the increase of systemic and intestinal inflammation (102, 103).

Furthermore, gut-derived peptide disturbances are also related to increased intestinal inflammation caused by obesity (104). The derived inflammatory signaling from obesity is associated with anatomic and physiologic changes in the intestine. The mucosa layer is composed of epithelial cells (enterocytes) connected by specialized proteins known as tight junctions (TJ) (105). These proteins are responsible for “filtering” the components that are absorbed by the intestinal enterocytes (105). An increase in TNF-α and IL-13 decreases TJ expression, increasing the chances of intestinal inflammation. Also, an increase in TJ in blood circulation is associated with the deleterious effects of obesity on intestinal integrity (106, 107). Treatments with peptides such as CCK can preserve the intestinal mucosa’s integrity and decrease TJ dysfunction (104). Furthermore, the gut microbiota is an essential component of TJ control, intestinal mucosa, and satiety regulation (108).

Several studies have shown that obese phenotypes are associated with the altered composition and low abundance of the gut microbiota (109–111). Gut microbiota can ferment indigestible fibers and produce SCFAs (109).
animals that ate a high-fat diet containing 10% fermentable flaxseed fiber, which increased total SCFA levels, gained less weight than those that ate without the fiber (112). These results agree with the SFCA’s being able to mediate the energy balance of obesity by increasing energy expenditure and fat oxidation (113). SCFAs can also protect adipocytes from leukocyte infiltration by attenuating interleukin-1β (IL-1β) and TNF-α expression, in addition to restoring the adiponectin production in high-fat-fed mice (114). Furthermore, SCFAs appear to be the “bridge” of communication between the gut microbiota and the brain (115). Due to this communication, the gut microbiota can regulate inflammation in the hypothalamus and is believed to be one of the avenues of appetite control and obesity treatment (116).

More recently, high BMI was associated with lower alpha diversity; however, the gut microbiota from obesogenic phenotypes may vary according to race/ethnicity, dietary components, or socioeconomic status (117). Moreover, some bacteria such as *F. prausnitzii*, *R. faecis*, *A. muciniphila*, *Prevotella*, and *Ruminococcus* have been associated with weight reduction (118, 119). More recently, *Akkermansia muciniphila* was shown to reduce gut barrier disruption and insulin resistance (120), where individuals with diabetes and obesity present a reduced abundance of this species, leading to some prospects in treating obesity (121). Moreover, obese mice supplemented with SCO-792, an available enteropeptidase inhibitor reported to have therapeutic effects on obesity and diabetes, increased the abundance of *A. muciniphila* (122). Besides, an increase in *Prevotella* in overweight adults has been related to significant weight reduction (123). Thus, the gut microbiota seems to participate in the brain-intestine axis due to the functions in the host’s metabolism and may play a role in treating obesity by regulating appetite (124, 125).

Obesity is also associated with immunological changes throughout the MGB axis (126, 127). Adipose tissue is considered an endocrine organ and secretes some proinflammatory proteins (adipokines), such as leptin, resistin, and angiopeptin-like protein 2 (ANGPTL2) (128). Leptin and ANGPTL2 stimulate the activation and proliferation of monocytes and macrophages (129, 130). Resistin drives inflammation by elevating TNF-α and IL-6, activating the Toll-like receptor (TLR) 4-affiliated pro-inflammatory pathway and developing insulin resistance (131). Excess adipose tissue can lead to these immune and metabolic changes (132, 133).

During obesity, the protective interleukins (II-17-producing Th17 cells, IL-10-secreting regulatory T (Treg) cells, and IL-22) are reduced (127, 134), while there is a more significant release of pro-inflammatory cytokines such as tumor necrosis factor (TNF-α) and interferon (IFNγ). This results in damage to the gut barrier expressed by reduced expression of epithelial tight junction proteins and antimicrobial proteins such as regenerating islet-derived protein 3 gamma (RegIIIγ) (135). This excessive permeability in the intestine is termed “leaky gut” and allows for translocation of bacteria products, triggering “metabolic endotoxemia” and systemic inflammation (136).

The studies presented here indicate the MGB axis as a complementary target for treating obesity due to its direct participation in controlling food satiety, macronutrient absorption, and inflammatory processes (39, 142). Despite preliminary evidence, further studies are needed, especially to highlight the impact of each element of the axis on the pathogenesis of obesity and the effect of this multifactorial disease on these target organs. Moreover, it is still necessary to investigate how different interventions can influence the MGB axis, such as dietary interventions, sleep, life stages, and physical activity.

**The impact of physical activity on the microbiota-gut-brain axis**

Muscle contraction in response to physical exercise promotes a series of acute and chronic physiological changes in the organism, many of which are associated with disease prevention and health improvement (143). Muscle contraction through exercise increases energy demand on muscle fibers, and the supply to vital organs is altered (144). Blood suppression in the gastrointestinal system depends on the intensity of the exercise. While mild-to-moderate exercise can preserve mucosal and improve intestinal motility, high-intensity exercise is associated with epithelial injury, enhanced permeability, reduced gastric motility, and other imbalances (144). These physiological changes in the intestine also generate several molecular changes in the MGB axis (Figure 3). Thus, it has been hypothesized that controlled physical training can improve intestine health, increase microbial diversity and abundance, and alter neurotransmitters that regulate appetite (17).

The role of exercise in appetite regulation related to obesity may be approached by investigating the acute effect of exercise or its chronic responses (14, 145). Acute exercise suppresses acylated ghrelin and increases GLP-1 and PYY, which could be associated with satiety control (145). The temporary suppression of appetite occurs around 60% of the VO₂ peak (146–150) and has been shown in different types of exercise, such as running (146, 147, 149), cycling (148, 151, 152), swimming (153), high-intensity interval exercise (154, 155) and resistance training (156) (see Table 2). However, peptide signaling may vary according to the exercise intensity and
volume, diet, temperature, trainability, and the period of the day the exercise is performed (18, 154, 174–177).

An experiment with an animal model showed that ghrelin levels increase after an acute bout of exercise, where this response was dependent on running distance or time (174). In addition, animals with low ghrelin receptors (GHSR-nulls) decreased endurance performance and food intake following high-intensity interval exercise (174). It was also shown that the CCK increases after acute exercise, which optimizes the satiety state (178). Moreover, healthy women submitted to sensitive high-intensity training presented increased levels of GLP-1 and a reduction in hunger compared to moderate exercise (155). On the other hand, the effects of activity on the MGB axis appear to be even more consistent (14). Physical training plays an anorectic role that seems to be enhanced with training, increasing leptin levels, glucose insulinotropic peptide (GIP), nestin-1, adiponectin, GLP-1, PP, OXM, and PYY (Figure 3 and Table 2). To date, no research has analyzed the changes of all these peptides simultaneously in the context of physical exercise.

Despite the replication in several modalities on appetite control, aerobic training seems more effective than resistance training in increasing the satiety of overweight and obese adults (179). However, in overweight and sedentary individuals, it has recently been observed that 12 weeks of resistance training decreased ghrelin and PYY concentrations more than the proposed aerobic protocol (180). These data demonstrate no consensus concerning the training modality to reduce overweight people’s appetite. Exercise is also able to change the functional anatomy characteristics of the intestine. Physical activity alone increased the thickness, height of villi, and the rats’ crypts’ depth submitted to a hypothalamic obesity condition (181). Exercise is also able to alter intestinal integrity through TJ (182). Some evidence shows that physical training increases the expression of zonulin, claudin, and occluding proteins (TJs), in addition to decreasing the concentration of circulating lipopolysaccharides (LPS), thus having a protective effect on the intestinal barrier (183), see Figure 3. However, intensity and volume determine the beneficial effect of exercise on intestinal permeability (144). More than 60 min of vigorous endurance training at 70% of the maximum work capacity led to increased intestinal permeability (144). Thus, depending on the applied dose of exercise, exercise can generate an antagonistic effect of obesity on the brain-intestine axis (11).

It has been known for a few years that exercise can also alter gut microbiota composition (15, 184). Some of these alterations include increased bacterial richness (α-diversity), butyrate-producing bacteria, and the abundance of A. muciniphila and Faecalibacterium prausnitzii (15, 185, 186). In obese children, the combination of 12 weeks of strength and endurance training was shown to neutralize changes in the microbiota caused by...
### TABLE 2 Possible changes by acute and chronic exercise in hormones/peptides that participate in MGB axis.

| Hormone / peptide | Subjects | Exercise Type | Exercise Intensity | Exercise Volume | Contributing Factor | Changes by exercise | Author |
|-------------------|----------|---------------|--------------------|----------------|--------------------|---------------------|--------|
| Ghrelin           | Healthy M and W (n=23) | Acute cycling | 75% VO2peak | 60 min | Ketone monoester drink or dextrose control isocaloric drink | ↓ | 165 |
| Peptide YY (PYY)  | Healthy M and W (n=72) | Acute cycling | 75% VO2peak | 60 min | Ketone monoester drink or dextrose control isocaloric drink | There was no significant difference in total PYY. † | 166 |
| Glucagon like peptide-1 (GLP-1) | Healthy M (n=10) | Acute cycling | high intensity session: 75% VO2 max, moderate intensity session: 50% VO2 max | 30 min, 3x week | Instant noodles and a piece of cheese: 532 kcal, 13.9% protein, 26.6% fat, and 59.5% carbohydrate | ↑ GLP-1 after exercise 30 min exercise | 167 |
| Cholecytokinin (CCK) | Sedentary obese M (n=55) | Chronic Aerobic | 75% FCmax | 5x wk/ 12 wks | 500-kcal energy deficit per session | There was no significant change after chronic exercise intervention | 168 |
| Pancreatic Polypeptide (PP) | Sedentary obese M and W (n=13) | Aerobic | 75% VO2peak (2weeks) | 60 min | 1,500 kcal intake for 12 h (6 meals every 2 h) | † Fasting PP after 15 days of exercise | 169 |
| Oxyntomodulin (OXM) | Healthy W and M (n=15) | Aerobic | (HIE) 70% VO2max, (MIE) 50%VO2max | HIE = 20min MIE = 30min | – | † Oxyntomodulin after chronic aerobic exercise only in the HIE group | 170 |
| Gastric Inhibitor Polypeptide OR glucose-dependent insulino tropic (GIP) | Pre-diabetic and obese W and M (n=22) | Chronic aerobic | 85% FCmax | 60 min 5x wk/ 12 wks | High glycemic index diet / low glycemic index diet. | The group with a low glycemic index diet showed † GIP compared to the group with a high glycemic index. | 171 |
| Gastrin           | Wistar rats M (n=24) | Swimming | – | 30 min | 50% food restriction | † Gastrin and improvement of intestinal hormonal dysfunction | 172 |
| Leptin            | Adolescent obese W and M (n=72) | Combined training; Aerobic training and physical leisure | – | 60 min | 6 months | † Leptin levels and reduced resistance | 173 |
| Adiponectin       | Healthy W and M (n=29) | Combined training | 60-70% cardiac reserve and 80% 1RM | 20 min | – | Adiponectin † 55% after exercise and there was a † in post-exercise compared to the control group. | 174 |
| Insulina          | Healthy W and M (n=32) | Cycling | 60-80% FCmax/ 60-80 RPM | – | Isocaloric diet | † Sensitivity; † insulin secretion; | 175 |
| Neuro peptide Y (NPY) | Athletes (n=12) | Paddle ergometer and Resistance training | 40-50% RM | 15h/20h for week | High carbohydrate diet | The NPY values in the exercise were significantly † immediately after and after 30 minutes. | 176 |
| Melanocortin      | Overweight to obese and postmenopausal W (n=23) | Resistance training | 8 RM, and resistance until muscle failure | – | 'Normal' diet throughout the intervention period and do not consume alcohol in the days before any blood collection. | Resistance training can modulate the expression of the melanocortin 3 receptor | 177 |
| Islet amyloid polypeptide (IAPP) or Amylin | Healthy M (n=7) | Incremental test on the treadmill | 60, 75, 90, 100% VO2max | 10, 10, 5, 2 min | Without alcohol 24h before the test | † Amylin levels in well-trained individuals | 178 |
| Orexin or Hypocretin | Healthy M (n=10) | Cycling ergometric | 75w and 60 RPM | 15 min | Without strenuous physical activity 7 days and without medication, alcohol or coffee | Thermoregulator during exercise; appetite control, | 179 |
| Visfatin (VF)     | Sedentary W (n=48) | Combined Training | 40% increased 60-75% FCmax | 45 min + 20 min | – | physical training and weight loss can † visfatin levels | 180 |

(Continued)
TABLE 2 Continued

| Hormone / peptide | Subjects | Exercise Type | Exercise Intensity | Exercise Volume | Contributing Factor | Changes by exercise | Author |
|-------------------|----------|---------------|--------------------|-----------------|--------------------|---------------------|--------|
| Nesfatin-1        | Overweight W with metabolic syndrome (n=60) | (EA) aerobic exercises; (ER) resistance exercises; (EC) combined exercises | (EA): 60-75% FCmax; (ER): 60 Increased 75 - 80% 1RM; (EC): EA and ER simultaneous | 30 and 60 min | No changes in habits | Nesfatin-1 † significantly after physical training in the three intervention groups. | (173) |

† - increase or gain; ↓ - reduction or loss; FCmax, Maximum Heart Rate; W, Woman; M, Male; min, minutes; n =, sample; wk/wks, week/week; HIE, High Intensity Exercise; MIE, Moderate Intensity Exercise.

(↑) Increase Secretion and Greater; (↓) Decrease Secretion and Decline; (wks) Weeks; (min) Minute.

Obesity, reducing the Proteobacteria phylum and Gammaproteobacteria class (187). This training protocol also increased the Blautia, Dialister, and Roseburia genera and the abundance of SCFA, leading to a similar status observed in healthy children (187). A recent study in overweight and obese adults showed that long-term training (6 months) demonstrated subtle microbiota changes and no relationship between alpha diversity and cardiorespiratory fitness or fat mass (19). In overweight older adults, regular exercise reshaped microbial composition and function alterations induced by aging (16). It is worth mentioning that the positive action of exercise on the microbiota and immune system depends on the intensity and volume of training and the individual’s trainability (188).

Physical exercise may also influence the MGB axis in pathophysiological contexts through bidirectional communication between the muscle, the intestine, and the brain (muscle-gut-brain axis) (188, 189). Skeletal muscle can act as an endocrine organ and release into the bloodstream molecules (PYY, irisin, myonectin, and others) called myokines (190, 191). There is some evidence that these myokines may act on appetite and changes in the gut microbiota (190, 192, 193). The skeletal muscle proteomic profile identified more than 300 myokines and these molecules perform various functions in the body, such as lipid and glucose metabolism, browning of white fat, bone formation, endothelial cell function, etc (191). The myokines IL-6, IL-7, IL-15 and leukemia inhibitory factor (LIF) also exert immune functions (194). In this sense, resistance training plus aerobic can increase the obese animals’ IL-7 expression (195). IL-7 is a vital myokine responsible for lymphocyte homeostasis and body fat reduction (196). Furthermore, since the IL-15/IL-15Rα gene transfer induced weight loss in obese animals (197), IL-15 is estimated to be a potential regulator of fat mass (198). Interestingly, obese mice trained for 12 weeks on a treadmill increased IL-15 mRNA expression and IL-15 immunoreactivity in muscle (199). Thus, further clinical studies are expected to better explain how muscle communicates with the immune system, gut, brain and gut microbiota in the context of obesity.

Conclusion and prospects

The current scientific literature presents a body of evidence indicating that obesity contributes to increased inflammatory signaling in the hypothalamus and increased appetite and gastric motility, in addition to being associated with enterocyte lesions and contributing to dysbiosis development (Figure 2 and Table 1). However, regular physical activity has an anti-inflammatory effect on the hypothalamus and regulates appetite by increasing anorexigenic peptides (leptin, GIP, nesfatin-1, adiponectin, GLP-1, PP, OXM, and PYY). Moreover, the thickness, height of villi, and depth of crypts improve intestinal integrity through tight junctions and reduce the impact of obesity on the gut microbiota (Figure 3 and Table 2).

Current evidence initially points to an antagonistic response promoted by exercise and obesity in the MGB-axis (157, 181, 187). However, despite initially presenting antagonistic effects, physical exercise can adversely affect the gastrointestinal system and its associated microbiota, mainly when performed in larger training volumes and hot environments with little hydration, as previously reviewed (144). Nevertheless, the above conclusions have been drawn from different clinical studies and, in several cases using animal models, as there is still no study aiming to combine all the MGB axis elements.

In this context, further studies are needed to identify the antagonistic elements and mechanisms promoted by physical exercise and obesity in the MGB axis. Although some “anti-obese” drugs have emerged, these drugs are ineffective in treating obesity (200). Thus, future studies that analyze these drugs added to a physical training program are interesting. Furthermore, the exercise dose-response must also be further investigated, considering its different modalities and variations in intensity and volume in healthy and obese individuals. Perhaps, more important than identifying the opposite signals promoted by both stimuli is to understand how exercise can mitigate and reverse the adverse effects of obesity through the modulation of the MGB axis.
Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Dietary patterns interact with the variations of 18q21.23 rs17782313 locus on the hypothalamic-pituitary axis. Overweight and obese humans.

Vibes in Parkinson’s disease: The microbiota-Gut-Brain axis.

Association with metabolic syndrome ingredients in obese individuals.

Satiety.

Attenuated peptide YY release in obese subjects is associated with reduced autonomic dysregulation: analysis of hypothalamic and autonomic candidate genes.

“The microbiota-Gut-Brain axis in health and obesity, and after RYGB.”

The role of hypothalamic inflammation in diet-induced obesity and its association with cognitive and mood disorders.

The in vivo assessment of the hypothalamic-pituitary-adrenal axis in obesity.

Expression of the short chain fatty acid receptor GPR41/FFAR3 in autonomic and somatic sensory ganglia.

Expression of the short chain fatty acid receptor GPR41/FFAR3 in autonomic and somatic sensory ganglia.

Thondam SK, Cuithbertson DJ, Wijlde JPL. The influence of glucose-dependent insulinotropic polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Peptides (2020) 125:170208. doi:10.1016/j.peptides.2019.170208

Mihalal TR, Washington MC, Newman KD, Heath JC, Sayegh AF. Combined gastric releasing peptide-29 and glucagon like peptide-1 reduce body weight more than each individual peptide in diet-induced obese male rats. Neuroendocrinology (2018) 67:71–8. doi:10.1007/s00057-017-1109-9

Myers MGf, Lebel RL, Seeley RJ, Schwartz MW. Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol Metab (2010) 21:643–51. doi:10.1016/j.tem.2010.08.002

Guerrero-Millo M. Adiponectin: an update. Diabetes Metab (2008) 34:12–8. doi:10.1016/j.diabet.2007.08.002

Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med (2013) 34:59–58. doi:10.1016/j.mam.2012.11.001

Wu Y, He H, Cheng Z, Bai Y, Ma X. The role of leptin and peptide YY and peptide YY in the development of obesity via gut-brain axis. Curr Protein Pept Sci (2019) 20:750–8. doi:10.2174/13892032206661901250150401

Girardet C, Butler AA. Neural melanocortin receptors in obesity and related metabolic disorders. Biochim Biophys Acta (2014) 1842:482–94. doi:10.1016/j.bbadis.2013.05.004

Lutz TA. Effects of amylin on eating and adiposity. Handb Exp Pharmacol (2012) 209:231–50. doi:10.1007/978-3-642-24716-3_10

Mishra S, Gupta V, Mishra S, Sachan R, Asthana A. Serum level of orexin-a, leptin, adiponectin and insulin in north Indian obese women. Diabetes Metab Syndr Obes (2017) 11 Suppl 2:S1041–8. doi:10.2147/DMS.S137491

Stastny J, Bierentova-Vaska J, Vasku A. Visfatin and its role in obesity development. Diabetes Metab Syndr (2012) 6:120–4. doi:10.1016/j.dms.2012.08.011

Huang X, Yang Z. Resistin’s, obesity and insulin resistance: the continuing disconnect between rodents and humans. J Endocrinol Invest (2016) 39:607–15. doi:10.1007/s40618-015-0408-2

Dionysopoulou S, Charmandari E, Bargiati A, Vlahos M, Mastorakos G, Valsamakis A. The role of hypothalamic inflammation in diet-induced obesity and its association with cognitive and mood disorders. Nutrients (2021) 13(2):498. doi:10.3390/nu13020498

Rand CM, Patwari PP, Rodikova E, Zhou L, Berry-Kravis EM, Wilsen RJ, et al. Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation: analysis of hypothalamic and autonomic candidate genes. Pediatr Res (2011) 70:375–8. doi:10.1203/PDR.0b013e318229474d

Agus A, Denizot J, Thervenot J, Martinez-Medina M, Massier S, Sauvanet P, et al. Western Diet induces a shift in microbiota composition enhancing susceptibility to adherent-invasive e. coli infection and intestinal inflammation. Sci Rep (2016) 6:19032. doi:10.1038/srep19032

Kofo F. Behavioral feeding circuit: Dietary fat-induced effects of inflammatory mediators in the hypothalamus. Front Endocrinol (Lausanne) (2020) 11:591559. doi:10.3389/fendo.2020.591559

Thaler JP, Yi CX, Schur EA, Guyenet SJ, Hwang BH, Dietrich MO, et al. Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest (2012) 122:153–62. doi:10.1172/JCI69960

Koch M, Horvath TL. Molecular and cellular regulation of hypothalamic melanocortin neurons controlling food intake and energy metabolism. Mol Psychiatry (2014) 19:752–61. doi:10.1038/mp.2014.30

Kim JD, Leeuva S, Diena S. Hormonal regulation of the hypothalamic-pituitary-adrenal axis in obesity. Front Physiol (2014) 5:480. doi:10.3389/fphys.2014.00480

Kuhnert P, Krude H, Biermann H. Melanocortin 4 receptor signalling. Importance for weight regulation and obesity treatment. Trends Mol Med (2019) 25:136–48. doi:10.1016/j.molmed.2018.12.002

Lotta LA, Mokrosinski J, Mendes de Oliveira E, Li C, Sharp SJ, Luan J, et al. Human gain-of-Function MC4R variants show signaling bias and protect against obesity. Cell (2019) 177:597–607.e9. doi:10.1016/j.cell.2019.03.044

Ayers KL, Glicksberg BS, Garfield AS, Longrich S, White JA, Yang P, et al. Melanocortin 4 receptor pathway dysfunction in obesity: Patient stratification aimed at MC4R agonist treatment. J Clin Endocrinol Metab (2018) 103:2861–12. doi:10.1210/jc.2018-00258

Kim SH, Ahn MB, Cho WK, Cho KS, Jung MH, Suh BK. The relation of obesity to hypertension. J Obes Saudi Med J (2019) 40:19–25. doi:10.5537/jomj.2019.2.22825

Alstibhi MN, Alhoury AM, Alhozali AM. Serum nesfatin-1 and galanin concentrations in the adult with metabolic syndrome. Relat to insulin resistance Obes Saudi Med J (2019) 40:19–25. doi:10.5537/jomj.2019.2.22825

Ravussin A, Youm YH, Sander J, Ryu S, Nguyen K, Varela L, et al. Loss of neuropeptide Y and peptide YY-36 and peptidylomol and can be additive in their effect on food intake in overweight and obese humans. Diabetes (2010) 59:1635–9. doi:10.2337/db09-1859

Cholecystokinin, peptide YY, ghrelin and high sensitive c-reactive protein in parkinson’s disease: The microbiota-Gut-Brain axis.
73. Pouloupanagioti A, Nikos S, Papadaki H. Nucleobindin-2/Nesfatin-1 in the human hypothalamus is reduced in obese subjects and caloricines with oxytocin, vasopressin, melanin-concentrating hormone, and cocaine- and amphetamine-regulated transcript. *Neuroendocrinology* (2019) 108:190–200. doi: 10.1159/000496731

74. Yang M, Zhang Z, Wang C, Li K, Li S, Boden G, et al. Nesfatin-1 action in the brain induces insulin sensitivity through Akt/AMPK/TORC2 pathway in diet-induced insulin resistant diabetes. *Diabetes* (2012) 61:1959–68. doi: 10.2337/db11-1755

75. Ozturk Orkan G. Effects of nesfatin-1 on food intake and hyperglycemia. *J Am Coll Nutr* (2020) 39:345–51. doi: 10.1080/07315724.2019.1646678

76. Zhai Y, Li SZ, Fan XT, Tian Z, Lu XQ, Dong J. Circulating nesfatin-1 levels and type 2 diabetes: A systematic review and meta-analysis. *J Diabetes Res* (2017) 2017:6780978. doi: 10.1155/2017/6780978

77. Adamiska E, Ostrowska L, Gorska M, Kretowski A. The role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes. *Pharmacol Ther* (2014) 9.69–76. doi: 10.1014/pj.2014.02498

78. Gribble FM, Reimann F. Metabolic messengers: glucagon-like peptide 1. *Nat Metab* (2021) 3:142–8. doi: 10.1038/s42255-021-00377-x

79. Ribeiro-Parenti L, Jarry AC, Gavin JB, Willemetz A, Le Beyec J, Sannier A, et al. Bariatric surgery induces a new gastric mucosa phenotype with increased functional glucagon-like peptide-1 expressing cells. *Nat Commun* (2021) 12:110. doi: 10.1038/s41467-020-20301-1

80. Roth CL, Perez FA, Whitlock KB, Elfers C, Yanojeski JA, Shoemaker AH, et al. A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity. *Diabetes Obes Metab* (2021) 23:363–73. doi: 10.1111/dom.14224

81. Jensterle M, Rizzo M, Janzer A. Glucagon-like peptide 1 and taste perception. From molecular mechanisms to potential clinical implications. *Int J Mol Sci* (2021) 22(2):902. doi: 10.3390/ijms2020902

82. Gaweith GR, de la Serre CB. The critical role of CCK in the regulation of food intake and diet-induced obesity. *Peptides* (2021) 138:170492. doi: 10.1016/j.peptides.2021.1074092

83. Lafferty RA, Pratt PR, Irwin N. Emerging therapeutic potential for peptide YY for obesity-diseases. *Peptides* (2018) 100:269–74. doi: 10.1016/j.peptides.2018.11.005

84. Moran TH, Bi S. Hyperphagia and obesity in OLETF rats lacking CCK-1 receptors. *Pharmacol Res* (2006) 53:1211–8. doi: 10.1016/j.phrs.2006.1857

85. Zhang L, Bijker MS, Herzog H. The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. *Pharmacol Ther* (2011) 133:91–113. doi: 10.1016/j.pharmthera.2011.03.011

86. Dumont Y, Cadeiux A, Pheng LH, Fournier A, St-Pierre S, Quirion R. Peptide YY derivatives as selective neuropeptide Y receptor YY1 and YY2 agonists devoided of activity for the Y3 receptor sub-type. *Brain Res Mol Brain Res* (2014) 246:320–4. doi: 10.1016/j.brainres.2014.09.010

87. Singer K, Morris DL, Oatmen KE, Wang T, DelProposto J, Mergian T, et al. Functional glucagon-like peptide-1 expressing cells. *Ann N Y Acad Sci* (2012) 1242. doi: 10.1177/000187381246000101

88. Dumont Y, Cadeiux A, Pheng LH, Fournier A, St-Pierre S, Quirion R. Peptide YY derivatives as selective neuropeptide Y receptor YY1 and YY2 agonists devoided of activity for the Y3 receptor sub-type. *Brain Res Mol Brain Res* (2014) 246:320–4. doi: 10.1016/j.brainres.2014.09.010

89. Monteleone P, Maj M. Dysfunctions of leptin, ghrelin, BDNF and endocannabinoids in eating disorders: beyond the homeostatic control of food intake and diet-induced obesity. *Front Pharmacol* (2013) 4:89. doi: 10.3389/fphar.2013.00031

90. Aoun A, Darwish F, Hamod N. The influence of the gut microbiome on obesity in adults and the role of probiotics, prebiotics, and symbiotics for weight loss. *Prev Nutr Food Sci* (2020) 25:113–23. doi: 10.3746/pnfs.2020.25.2.113

91. Amabebe E, Robert FO, Agbalalah T, Orubu ESF. Microbial dysbiosis- inflammation: the linking mechanism and the complications. *Front Immunol* (2020) 11:68. doi: 10.3389/fimmu.2020.00942

92. Christian C, Gualda S, Ahmadi M, Bahrami A. Obesity and inflammation: the linking mechanism and the complications. *Front Immunol* (2020) 11:98. doi: 10.3389/fimmu.2020.01974

93. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. *Nat Rev Immunol* (2011) 11:85–97. doi: 10.1038/nri2921

94. Zhihui C, Mills C, Matter K, Balda MS. Tight junctions: from simple barriers to multifunctional molecular gates. *Nat Rev Mol Cell Biol* (2020) 21:764–80. doi: 10.1038/s41584-020-00359-6

95. Genev G, Aagunno D, Soula HA, Dong L, Trystram L, Assmann K, et al. Increased jejunal permeability in human obesity is revealed by a lipid challenge and is linked to inflammation and type 2 diabetes. *J Pathol* (2018) 246:217–30. doi: 10.1002/path.5134

96. Chang CS, Kao CY. Current understanding of the gut microbiota shaping mechanisms. *J Med BioSci* (2019) 26:59. doi: 10.11698/s8929-019-0554-5

97. Holmes ZC, Silverman JD, Dressman HK, Wei Z, Dollow EP, Armstrong SC, et al. Short-chain fatty acid production by gut microbiota from children with obesity differs according to prebiotic choice and bacterial community composition. *mBio* (2020) 11(4):e00914-12. doi: 10.1128/mBio.00914-20

98. Amabebe E, Robert FO, Agbalalah T, Orubu ESF. Microbial dysbiosis- inflammation: the linking mechanism and the complications. *Front Immunol* (2020) 11:68. doi: 10.3389/fimmu.2020.00942

99. Christian C, Gualda S, Ahmadi M, Bahrami A. Obesity and inflammation: the linking mechanism and the complications. *Front Immunol* (2020) 11:98. doi: 10.3389/fimmu.2020.01974

100. Aoun A, Darwish F, Hamod N. The influence of the gut microbiome on obesity in adults and the role of probiotics, prebiotics, and symbiotics for weight loss. *Prev Nutr Food Sci* (2020) 25:113–23. doi: 10.3746/pnfs.2020.25.2.113

101. Amabebe E, Robert FO, Agbalalah T, Orubu ESF. Microbial dysbiosis- induced obesity: role of gut microbiota in the development of metabolic syndrome. *J Transl Med* (2013) 11:25. doi: 10.1186/1479-5876-11-25

102. Ribeiro et al. 2022. Frontiers in Endocrinology | www.frontiersin.org | 12 | 10.3389/fendo.2022.927170
Angiopoietin-like protein 2 promotes chronic adipose tissue in
Ribeiro et al. 10.3389/fendo.2022.927170

Gut permeability through the regulation of tight junctions.

Front Immunol (2015) 12:15006. doi: 10.3390/fimmunol.2015.03337

Challenkov C, Choi Y, Kim DK, Park HT, Ghim J, Kwon Y, et al. Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions. Exp Mol Med (2018) 50: e450. doi: 10.1038/emm.2017.282

Xu Y, Wang N, Tan HY, Li S, Zhang C, Feng Y. Function of akkermansia muciniphila in obesity. Interactions with lipid metabolism, immune response and gut systems. Front Microbiol (2020) 11:2129. doi: 10.3389/fmicb.2020.00219

Sugama J, Moritoh Y, Tsuchimori K, Watanabe M. Enteropeptidase inhibition improves obesity by modulating gut microbiota composition and enterobacterial metabolites in diet-induced obese mice. Pharmacol Res (2021) 163:105337. doi: 10.1016/j.phrs.2021.105337

Christensen L, Vuhløen S, Roager HM, Nielsen DS, Krych L, Kristensen M, et al. Prevotella abundance predicts weight loss success in healthy, overweight adults consuming a whole-grain diet ad libitum: A Post hoc analysis of a 6-wk randomized controlled trial. J Nutr (2019) 149:2174–81. doi: 10.1093/jn/nxz198

Zawada A, Rychter AM, Ratajczak AE, Lisiecka-Masian A, Dobrowolska A, Kreß-Kazmierczak I. Does gut-microbiome interaction protect against obesity and obesity-associated metabolic disorders? Microorganisms (2020) 9:1–18. doi: 10.3390/microorganisms9010018

Kuhne SG, Stengel A. Alteration of peptidergic gut-brain signaling under conditions of obesity. J Physiol Pharmacol (2017) 152:1998–2010. doi: 10.1016/j.jphysparaproc.2017.05.020

Eaton JM, Anderton J, Ewald AM. Combined effects of aerobic exercise and high-carbohydrate meal on appetite, energy intake and circulating concentrations of acylated ghrelin. Appetite (2010) 54:492–8. doi: 10.1016/j.appet.2010.02.002

King JA, Wasse LK, Stendel DJ. Influence of prolonged treadmill running on appetite, energy intake and circulating concentrations of acylated ghrelin. Appetite (2011) 57:145–53. doi: 10.1016/j.appet.2011.08.003

Kuhne SG, Stengel A. Alteration of peptidergic gut-brain signaling under conditions of obesity. J Physiol Pharmacol (2017) 152:1998–2010. doi: 10.1016/j.jphysparaproc.2017.05.020

Eaton JM, Anderton J, Ewald AM. Combined effects of aerobic exercise and high-carbohydrate meal on appetite, energy intake and circulating concentrations of acylated ghrelin. Appetite (2010) 54:492–8. doi: 10.1016/j.appet.2010.02.002

King JA, Wasse LK, Stendel DJ. Influence of brisk walking on appetite, energy intake, and plasma acylated ghrelin. Med Sci Sports Exerc (2010) 42:485–93. doi: 10.1249/MSS.0b013e3181b1a4c4

Becker GF, Macdonald RC, Chun A, Shibata Y, Libman O, Laitman D. Leptin stimulates adipocyte differentiation in 3T3-L1 adipocytes. J Biol Chem (1987) 262:16927–32. doi: 10.1021/ja00183a002

Scheithauer TPM, Rampanelli E, Nieuwdorp M, Vallance BA, Verchere CB, van Raalte DH, et al. Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes. Front Immunol (2020) 11:57731. doi: 10.3389/fimmu.2020.57731

Everard A, Belzer C, Geurts I, Ouwerverk JP, Druart C, Bindels LB, et al. Cross-talk between akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U.S.A. (2013) 110:9966–71. doi: 10.1073/pnas.1219451110

Forte N, Fernandez-Rilo AC, Palomá L, Di Marzo V, Cristina L. Obesity affects the microbiota-Gut-Brain axis and the regulation thereof by endocannabinoids and related mediators. Int J Mol Sci (2020) 21(3):1554. doi: 10.3390/ijms21031554

Rocki KS, Witzczak CA, Goodyear LJ. Signaling mechanisms in skeletal muscle: acute responses and chronic adaptations to exercise. J UMBB Life (2008) 60:44–53. doi: 10.1021/jb810211

Costa RJ, Snij RJMP, Kitic CM, Gibson PR. Systematic review: exercise-induced gastrointestinal syndrome-implications for health and intestinal disease. Aliment Pharmacol Ther (2017) 46:246–56. doi: 10.1111/app.14157

Douglas JA, Deighton K, Atkinson JM, Sanz-Sarraf V, Stendel DJ, Atkinson G. Acute exercise and appetite-regulating hormones in overweight and obese individuals: A meta-analysis. J Obes (2016) 2016:264365. doi: 10.1155/2016/264365

Broom DR, Stendel DJ, Bishop NC, Burns SF, Miyashita M. Exercise-induced suppression of acylated ghrelin in humans. J Physiol (2007) 575:2615–71. doi: 10.1111/j.1469-7990.2007.05709.x

Broom DR, Batterham RL, King JA, Stendel DJ. Influence of resistance and aerobic exercise on hunger, circulating levels of acylated ghrelin, and peptide YY in healthy males. Am J Physiol Regul Integr Comp Physiol (2009) 296:829–35. doi: 10.1152/ajpregu.90709.2008

Ueda SY, Yoshikawa T, Katsura Y, Utsu T, Nakao H, Fujimoto S. Changes in gut hormone levels and negative energy balance during aerobic exercise in obese young males. J Endocrinol (2009) 201:151–9. doi: 10.1677/JOE-08-0500

King JA, Miyashita M, Waske LK, Stendel DJ. Influence of prolonged treadmill running on appetite, energy intake and circulating concentrations of acylated ghrelin. Appetite (2010) 54:492–8. doi: 10.1016/j.appet.2010.02.002

King JA, Wasse LK, Broom DR, Stendel DJ. Influence of brisk walking on appetite, energy intake, and plasma acylated ghrelin. Med Sci Sports Exerc (2010) 42:485–93. doi: 10.1249/MSS.0b013e3181b1a4c4

Reilly JJ, Orange RJ, Thomson R, Smith EJ, Thomas G, Prior S. Changes in circulating hormones and appetite in response to exercise in healthy men. Int J Obes Related Med Biol Sci (2005) 29:1035–44. doi: 10.1038/sj.ijo.0803136

Gopal H, Athanasiou A, Plein S, Lee JY, Whittaker J, Christian P, et al. Effect of exercise on appetite and energy intake in obese women: A meta-analysis. Int J Obes (2013) 37:896–907. doi: 10.1038/ijo.2012.205

Kanaley JA, Heden TD, Liu Y, Whaley-Connell AT, Chockalingam A, Dilllperger KC, et al. Short-term aerobic exercise training increases postprandial

Frontiers in Endocrinology | www.frontiersin.org 12 | March 2022 | Volume 13 | Article 927170

Ribeiro et al.
pancreatic polypeptide but not peptide YY concentrations in obese individuals. Int J Obes (2013) 38:266–71. doi: 10.1038/j.ijo.2013.84

16. Wynne K, Park AJ, Small CJ, Moeran K, Gheare MA, Frost GS, et al. Oxytocinmodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (2006) 30:1729–36. doi: 10.1038/sj.ijo.0803344

17. Soltmann TP, Haus JM, Kelly KR, Cook MD, Filion J, Rocroi M, et al. A low-glycemic index diet combined with exercise reduces insulin resistance, postprandial hyperinsulinemia, and glucose-dependent insulinotropic polypeptide responses in obese, prediabetic humans. Am J Clin Nutr (2010) 92:1359–68. doi: 10.3945/ajcn.2010.29771

18. Shaodong C, Hailong Z, Manting L, Guohui L, Zhengxiao Z, Zhang MY. Research of influence and mechanism of combining exercise with diet control on a model of lipid metabolism rat induced by high fat diet. Lipids Health Dis (2013) 12:21. doi: 10.1186/1476-511X-12-21

19. Acker-D’Elia C, Carmer J, Bueno CR Jr., Campos RM, Sanches PL, Clemente AP, et al. Effects of different physical exercises on leptin concentration in obese adolescents. Int J Sports Med (2014) 35:164–71. doi: 10.1055/s-0034-1345128

20. Markowski MM, Carrillo AE, Timmerman KL, Jennings K, Coen PM, Pence BD, et al. Exercise training modifies ghrelin and adiponectin concentrations and is related to inflammation in older adults. J Gerontol A Biol Sci Med Sci (2014) 69:675–81. doi: 10.1093/gerona/glt332

21. Ding C, Choui YUC, Chan Z, Lo J, Choo J, Ding BTK, et al. Dose-dependent effects of exercise and diet on insulin sensitivity and secretion. Med Sci Sports Exerc (2019) 51:2109–16. doi: 10.1249/MSS.00000000000018020

22. Ramson B, Jurimae J, Jurimae T, Maestu J. The effect of 4-week training period on plasma neuropeptide y, leptin and ghrelin responses in male rowers. J Appl Physiol (2017) 157:437. doi: 10.1152/japplphysiol.00437.2017

23. Hennagen TM, Phillips MD, Check DJ, Kirk KM, Barber JJ, Stewart LK. The melanocortin 3 receptor: a novel mediator of exercise-induced in skeletal muscle. Int J Obes (2011) 35:43. doi: 10.1038/ijo.2010.91

24. Hennagen TM, Phillips MD, Check DJ, Kirk KM, Barber JJ, Stewart LK. The melanocortin 3 receptor: a novel mediator of exercise-induced in skeletal muscle. Int J Obes (2011) 35:43. doi: 10.1038/ijo.2010.91

25. Kesavamurthy R, Akhtar N, Varma NK, Choudhury A, Bhargava M, Gupta S, et al. Effect of acute sprint exercise on myokines and food intake in rats. Physiol Behav (2021) 233:113355. doi: 10.1016/j.physbeh.2021.113355

26. Ghafari-Niaaki A, Sahghebjo M, Soltani R, Kirwan JP. Plasma ghrelin is increased after high-intensity exercise. PLoS One (2012) 7:e40351. doi: 10.1371/journal.pone.0040351

27. Lari MB, Zakeri M, Kargar S, Shamsi M, Mohammadianfardzad R, Bagheri-Hosseinabad Z, Assadi MR, et al. Effect of 12 weeks of aerobic training on plasma visfatin and eotaxin levels. Br J Sports Med (2014) 48:980–6. doi: 10.1136/bjsports-2012-091585

28. Shin HE, Kwak SE, Zhang DD, Lee J, Yoon JK, Cho HS, et al. Effects of treadmill exercise on the regulation of tight junction proteins in aged mice. Exp Gerontol (2020) 141:110777. doi: 10.1016/j.exger.2020.110777

29. Matsutomo M, Inoue N, Tsukahara T, Ushida K, Chiji H, Matusbara N, et al. Voluntary running exercise alters microbiota composition and increases n-butyrate concentration in the rat cecum. Biosci Biotechnol Biochem (2008) 72:572–6. doi: 10.1271/bbb.70474

30. Estaki M, Pither J, Baumeister P, Little JP, Gill SK, Ghosh S, et al. Cardiorespiratory fitness as a predictor of intestinal microbial diversity and distinct metagenomic functions. Microbiome (2016) 4:42. doi: 10.1186/s40168-016-0189-9

31. Ortiz-Alvarez L, Xu H, Martinez-Tellez B. Influence of exercise on the human gut microbiota of healthy adults: A systematic review. Clin Transl Gastroenterol (2021) 12:100126. doi: 10.1016/j.cttg.2021.100126

32. Quirroga R, Nistal E, Iribarren B, Peruzzo D, Juez-Fernandez M, Martinez-Florer S, et al. Exercise training modulates the gut microbiota profile and improves inflammatory signaling pathways in obese children. Exp Mol Med (2020) 52:1048–61. doi: 10.1038/s12276-020-0459-0

33. Tincanesi A, Laurenti F, Tan C, Nouvenne A, Ridolo E, Meschi T. Exercise and immune system as modulators of intestinal microbiome: implications for the gut-muscle axis hypothesis. Exerc Immunol Rev (2019) 25:84–95.

34. de Sire R, Rizzatti G, Ingravalle F, Pizzoferrato M, Vetto L, Vipoto L, et al. Skeletal muscle-gut axis: emerging mechanisms of sarcopenia for intestinal and extra intestinal diseases. Minerva Gastroenterol Dietal (2017) 64:351–62. doi: 10.23736/S1221-418X.17.05211-4

35. Laurens C, Bergouignan A, Moro C. Exercise-released myokines in the control of energy metabolism. Front Physiol (2020) 11:91. doi: 10.3389/fphys.2020.00091

36. Severinsen MCK, Pedersen BK. Muscle-organ crosstalk: The emerging roles of myokines. Endocr Rev (2020) 41(4):594–609. doi: 10.1210/endcr/bee2016-0016

37. Blikk J, Mazur-Bialy AI, Surmiak M, Hubalewska-Mazgaj M, Pokorski J, Nitecki J, et al. Effect of acute sprint exercise on myokines and food intake hormones in young healthy men. Int J Mol Sci (2020) 21(22):8848. doi: 10.3390/ijms21228848

38. Suriano F, Van Hul M, Cani PD. Gut microbiota and regulation of myokine-adipokine function. Curr Opin Pharmacol (2020) 52:9–17. doi: 10.1016/j.coph.2020.03.006

39. Koh J, Nikosrat N, Campbell KL. Exercise training and immune crosstalk in breast cancer microenvironment: exploring the paradigms of exercise-induced immune modulation and exercise-induced myokines. Am J Transl Res (2014) 6:432–38.

40. Ahn N, Kim K. Effects of aerobic and resistance exercise on myokines in high fat diet-induced middle-aged obese rats. Int J Environ Res Public Health (2020) 17(8):2685. doi: 10.3390/ijerph17082685

41. Lucas S, Taront S, Magnan C, Faucconier L, Delacre M, Macia L, et al. Interleukin-7 regulates adipose tissue mass and insulin sensitivity in high-fat diet-fed mice through lymphocyte-dependent and independent mechanisms. PLoS One (2012) 7:e40351. doi: 10.1371/journal.pone.0040351

42. Sun H, Ma Y, Gao M, Liu D. IL-15/sIL-15Ralpha gene transfer induces weight loss and improves glucose homostasis in obese mice. Gene Ther (2016) 23:349–56. doi: 10.1038/gt.2016.4

43. Duan X, Li F, Wang W, Guo Q, Wen C, Li Y, et al. Interleukin-15 in obesity and metabolic dysfunction: current understanding and future perspectives. Obes Rev (2017) 18:1147–58. doi: 10.1111/obr.12567

44. Yang H, Chang J, Chen W, Zhao L, Qu B, Tang C, et al. Treadmill exercise promotes interleukin 15 expression in skeletal muscle and interleukin 15 receptor alpha expression in adipose tissue of high-fat diet rats. Endocrine (2013) 43:579–85. doi: 10.1007/s12020-012-9009-6

45. Muller TD, Bluhm M, Tischp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discovery (2022) 21:201–23. doi: 10.1038/s41573-021-00337-8